PICO Portalanswers from OpenAlex & ORCID
Mark D. Pegram
ResearcherPublications, citations & collaboration network
Mark D. Pegram is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Mark D. Pegram have?
PICO Portalindexed works
Mark D. Pegram has 421 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mark D. Pegram have?
PICO Portalcitation count
Mark D. Pegram has 41,970 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Mark D. Pegram?
PICO Portalh-index
Mark D. Pegram has an h-index of 67 in OpenAlex.
What is the i10-index of Mark D. Pegram?
PICO Portali10-index
Mark D. Pegram has an i10-index of 169 in OpenAlex.
What is the ORCID of Mark D. Pegram?
PICO Portalorcid
The ORCID for Mark D. Pegram is on the source record.
What is the OpenAlex record for Mark D. Pegram?
PICO Portalopenalex
The OpenAlex for Mark D. Pegram is on the source record.
What are the most-cited papers on Mark D. Pegram?
PICO Portalmost cited works
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, H. Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, Mark D. Pegram, José Baselga, Larry Norton
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Nancy U. Lin, Virginia F. Borges, Vandana G. Abramson, Carey K. Anders, Philippe L. Bédard, Mafalda Oliveira, Erik Jakobsen, Thomas Bachelot, Shlomit Strulov Shachar, Volkmar Müller, Sofía Braga, François P. Duhoux, Richard Greil, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Gabriel N. Hortobágyi, Ian E. Krop, Sibylle Loibl, Mark D. Pegram, Dennis J. Slamon, Maria Corinna Palanca-Wessels, Luke Walker, Wentao Feng, Eric P. Winer
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Clare Taylor, Dawn L. Hershman, Nina Shah, Nicole Suciu‐Foca, Dan P. Petrylak, Robert N. Taub, Linda T. Vahdat, Bin Cheng, Mark D. Pegram, Keith L. Knutson, Raphael Clynes